Unfolding the role of protein misfolding in neurodegenerative diseases

Nature Reviews Neuroscience

Volumn 4, Issue 1, 2003, Pages 49-60

  Soto, Claudio ^a  

^a Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; HUNTINGTIN; PRION PROTEIN; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROTOXICITY; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; REVIEW; ANIMAL; BRAIN; BRAIN LEVEL; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; BRAIN CHEMISTRY; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING;

EID: 0037264120     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1007     Document Type: Article

References (148)

1. Carrell, R. W. & Lomas, D. A. Conformational disease. Lancet 350, 134-138 (1997).
2. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329-332 (1999).
3. Soto, C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 498, 204-207 (2001).
4. Martin, J. B. Molecular basis of the neurodegenerative diseases. N. Eng. J. Med. 340, 1970-1980 (1999).
5. Glenner, G. G. & Wong, C. W. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984).
6. Grundke-Iqbal, I. et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089 (1986).
7. Forno, L. S. Neuropathology of Parkinson disease. j. Neuropathol. Exp. Neurol. 55, 259-272 (1996).
8. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839-840 (1997).
9. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
10. Bruijn, L. I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854 (1998).
11. Bolton, D. C., McKinley, M. P. & Prusiner, S. B. Identification of a protein that purifies with the scrapie prion. Science 218, 1309-1311 (1982).
12. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991).
13. Gutekunst, C. A. et al. Nuclear and neuropil aggregates in Huntington’s disease: relationship to neuropathology. J. Neurosci. 19, 2522-2534 (1999).
14. McKeith, I. G. et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113-1124 (1996).
15. Hardy, J. & Gwinn-Hardy, K. Genetic classification of primary neurodegenerative disease. Science 282, 1075-1079 (1998).
16. Katzman, R. et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138-144 (1988).
17. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704-706 (1991).
18. Polymeropoulos, M. H. et al. Mutation in the a-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045-2047 (1997).
19. The Huntington’s Disease Collaborative Research Group (HDCRG). A novel gene containing a trinucleotide repeat that is unstable on Huntington’s disease chromosomes. Cell 72, 971-983 (1993).
20. Hsiao, K. et al. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature 338, 342-345 (1989).
21. Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62 (1993).
22. Games, D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527 (1995).
23. Masliah, E. et al. Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
24. Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264, 1772-1775 (1994).
25. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
26. Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (1997).
27. Hsiao, K. K. et al. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 250, 1587-1590 (1990).
28. Moechars, D. et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492 (1999).
29. Klement, I. A. et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53 (1998).
30. Prusiner, S. B. Prions. Proc. Natl Acad. Sci. USA 95, 13363-13383 (1998).
31. Kane, M. D. et al. Evidence for seeding of β-amyloid by intracerebral infusion of Alzheimer brain extracts in β -amyloid precursor protein-transgenic mice. J. Neurosci. 20, 3606-3611 (2000).
32. Lund mark, K. et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc. Natl Acad. Sci. USA 99, 6979-6984 (2002).
33. Xing, Y. et al. Transmission of mouse senile amyloidosis. Lab. Invest. 81, 493-499 (2001).
34. Wickner, R. B. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264, 566-569 (1994).
35. Uptain, S. M. L. & Lindquist, S. Prions as protein-based genetic elements. Annu. Rev. Microbiol. 56, 703-741 (2002).
36. Cohen, A. S. & Calkins, E. Electron microscopic observation on a fibrous component in amyloid of diverse origins. Nature 183, 1202-1203 (1959).
37. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729-739 (1997).
38. Serpell, L. C., Blake, C. C. & Fraser, P. E. Molecular structure of a fibrillar Alzheimer’s Aβ fragment. Biochemistry 39, 13269-13275 (2000).
39. Barrow, C. J., Yasuda, A., Kenny, P T. & Zagorski, M. G. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer’s disease. Analysis of circular dichroism spectra. J. Mol. Biol. 225, 1075-1093 (1992).
40. Pan, K. M. et al. Conversion of a-helices into β-sheet features in the formation of scrapie prion poteins. Proc. Natl Acad. Sci. USA 90, 10962-10966 (1993).
41. Conway, K. A., Harper, J. D. & Lansbury, P T. Fibrils formed in vitro from a-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39, 2552-2563 (2000).
42. Chen, S., Berthelier, V, Hamilton, J. B., O’Nuallain, B. & Wetzel, R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41, 7391-7399 (2002).
43. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. & Crowther, R. A. Fiber diffraction of synthetic a-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl Acad. Sci. USA 97, 4897-4902 (2000).
44. Sadqi, M. et al. α-Helix structure in Alzheimer’s disease aggregates of tau-protein. Biochemistry 41, 7150-7155 (2002).
45. Teplow, D. B. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid 5, 121-142 (1998).
46. Castaño, E. M. et al. In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer’s disease β-protein. Biochem. Biophys. Res. Commun. 141, 782-789 (1986).
47. Hilbich, C., Kisters-Woike, B., Reed, J., Masters, C. L. & Beyreuther, K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer’s disease βA4 peptides. J. Mol. Biol. 228, 460-473 (1992).
48. Jarrett, J. T., Berger, E. P. & Lansbury, P. T. Jr. The C-terminus of the β protein is critical in amyloidogenesis. Ann. NY Acad. Sci. 695, 144-148 (1993).
49. Soto, C., Castaño, E. M., Frangione, B. & Inestrosa, N. C. The α-helical to β -strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J. Biol. Chem. 270, 3063-3067 (1995).
50. Wood, J. D., Wetzel, R., Martin, J. D. & Hurle, M. R. Prolines and amyloidogenicity in fragments of the Alzheimer’s peptide β /A4. Biochemistry 34, 724-730 (1995).
51. Tagliavini, F. et al. Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc. Natl Acad. Sci. USA 90, 9678-9682 (1993).
52. Ueda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282-11286 (1993).
53. Zoghbi, H. Y. & Orr, H. T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
54. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558 (1997).
55. Perutz, M. F., Johnson, T., Suzuki, M. & Finch, J. T. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl Acad. Sci. USA 91, 5355-5358 (1994).
56. DePace, A. H., Santoso, A., Hillner, P. & Weissman, J. S. A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion. Cell 93, 1241-1252 (1998).
57. Mrak, R. E., Griffin, S. T. & Graham, D. I. Aging-associated changes in human brain. J. Neuropathol. Exp. Neurol. 56, 1269-1275 (1997).
58. Scherzinger, E. et al. Self-assembly of polyglutamine- containing huntingtin fragments into amyloid-like fibrils: implications for Huntington’s disease pathology. Proc. Natl Acad. Sci. USA 96, 4604-4609 (1999).
59. Wood, S. J. et al. α-Synuclein fibrillogenesis is nucleation- dependent. Implications for the pathogenesis of Parkinson’s disease. J. Biol. Chem. 274, 19509-19512 (1999).
60. LeVine, H. III. Soluble multimeric Alzheimer β(1-40) pre- amyloid complexes in dilute solution. Neurobiol. Aging 16, 755-764 (1995).
61. Kuo, Y. M. et al. Water-soluble A β (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081 (1996).
62. Lambert, M. P et al. Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448-6453 (1998).
63. Walsh, D. M. et al. Naturally secreted oligomers of amyloid-P protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
64. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M. & Teplow, D. B. Amyloid -β protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372 (1997).
65. Walsh, D. M. et al. Amyloid β -protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952 (1999).
66. Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. Jr. Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer’s disease. Biochemistry 38, 8972-8980 (1999).
67. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by α mutant α-synuclein linked to early- onset Parkinson disease. Nature Med. 4, 1318-1320 (1998)
68. Hyman, B. T. & Van Hoesen, G. W. Neuron numbers in Alzheimer’s disease: cell-specific pathology. Neurobiol. Aging 8, 555-556 (1987).
69. Myers, R. H. et al. Decreased neuronal and increased oligodendroglial densities in Huntington’s disease caudate nucleus. J. Neuropathol. Exp. Neurol. 50, 729-742 (1991).
70. Hughes, J. T. Pathology of amyotrophic lateral sclerosis. Adv. Neurol. 36, 61-74 (1982).
71. Gray, F. et al. Neuronal apoptosis in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. 58, 321-328 (1999).
72. Mattson, M. P. Apoptosis in neurodegenerative disorders. Nature Rev. Mol. Cell Biol. 1, 120-129 (2000).
73. Reaume, A. G. et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genet. 13, 43-47 (1996).
74. Borchelt, D. R. et al. Superoxide dismutase 1 subunits with mutations linked to familial amyotrophic lateral sclerosis do not affect wild-type subunit function. J. Biol. Chem. 270, 3234-3238 (1995).
75. Cattaneo, E. et al. Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci. 24, 182-188 (2001).
76. Dragatsis, I., Levine, M. S. & Zeitlin, S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nature Genet. 26, 300-306 (2000).
77. Martins, V. R. et al. Cellular prion protein: on the road for functions. FEBS Lett. 512, 25-28 (2002).
78. Chiarini, L. B. et al. Cellular prion protein transduces neuroprotective signals. EMBO J. 21, 3317-3326 (2002).
79. Kuwahara, C. et al. Prions prevent neuronal cell-line death. Nature 400, 225-226 (1999).
80. Kurschner, C. & Morgan, J. I. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. Brain Res. Mol. Brain Res. 30, 165-168 (1995).
81. Bounhar, Y, Zhang, Y., Goodyer, C. G. & LeBlanc, A. Prion protein protects human neurons against Bax-mediated apoptosis. J. Biol. Chem. 276, 39145-39149 (2001).
82. Xu, X. et al. Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc. Natl Acad. Sci. USA 96, 7547-7552
83. da Costa, C. A., Ancolio, K. & Checler, F. Wild-type but not Parkinson’s disease-related ala-53 → Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065-24069 (2000).
84. Zheng, H. et al. Mice deficient for the amyloid precursor protein gene. Ann. NY Acad. Sci. 777, 421-426 (1996).
85. Abeliovich, A. et al. Mice lacking α -synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252 (2000).
86. Bueler, H. et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-582 (1992).
87. C and its homologue Dpl. Trends Neurosci. 25, 150-154 (2002).
88. Mallucci, G. R. et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21, 202-210 (2002).
89. Bush, A. I. Metals and neuroscience. Curr. Opin. Chem. Biol. 4, 184-191 (2000).
90. Loo, D. T. et al. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc. Natl Acad. Sci. USA 90, 7951-7955 (1993).
91. Forloni, G. et al. Neurotoxicity of a prion protein fragment. Nature 362, 543-546 (1993).
92. Lunkes, A. & Mandel, J. L. A cellular model that recapitulates major pathogenic steps of Huntington’s disease. Hum. Mol. Genet. 7, 1355-1361 (1998).
93. El-Agnaf, O. M. et al. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Lett. 440, 71-75 (1998).
94. Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511 (2002).
95. Yan, S. D. et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nature Med. 6, 643-651 (2000).
96. Cummings, C. J. et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genet. 19, 148-154 (1998).
97. Ii, K., Ito, H., Tanaka, K. & Hirano, A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56, 125-131 (1997).
98. Arispe, N., Rojas, E. & Pollard, H. B. Alzheimer disease amyloid-β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl Acad. Sci. USA 90, 567-571 (1993).
99. Lin, M. X., Mirzabekov, T & Kagan, B. L. Channel formation by a neurotoxic prion protein fragment. J. Biol. Chem. 272, 44-47 (1997).
100. Behl, C., Davis, J. B., Lesley, R. & Schubert, D. Hydrogen peroxide mediates amyloid-β toxicity. Cell 77, 817-827 (1994).
101. Hsu, L. J. et al. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410 (2000).
102. Tompkins, M. M. & Hill, W. D. Contribution of somal Lewy bodies to neuronal death. Brain Res. 775, 24-29 (1997).
103. Bondareff, W., Mountjoy, C. Q., Roth, M. & Hauser, D. L. Neurofibrillary degeneration and neuronal loss in Alzheimer’s disease. Neurobiol. Aging 10, 709-715 (1989).
104. Watase, K. et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919 (2002).
105. Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66 (1998).
106. Hartley, D. M. et al. Protofibrillar intermediates of amyloid P-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884 (1999).
107. Goldberg, M. S. & Lansbury, P. T. Jr. Is there α cause- and-effect relationship between a-synuclein fibrillization and Parkinson’s disease? Nature Cell Biol. 2, E115-E119 (2000).
108. Hyman, B. T., Marzloff, K. & Arriagada, P. V. The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggest a dynamic balance between amyloid deposition and dissolution. J. Neuropathol. Exp. Neurol. 52, 594-600 (1993).
109. Kim, S., Nollen, E. A., Kitagawa, K., Bindokas, V. P. & Morimoto, R. I. Polyglutamine protein aggregates are dynamic. Nature Cell Biol. 4, 826-831 (2002).
110. McGeer, P. L. & McGeer, E. G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21, 195-218 (1995).
111. Wyss-Coray, T. & Mucke, L. Inflammation in neurodegenerative disease — a double-edged sword. Neuron 35, 419-432 (2002).
112. Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S. & Selkoe, D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24, 173-182 (1989).
113. Sapp, E. et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172 (2001).
114. Kawamata, T., Akiyama, H., Yamada, T. & McGeer, P. L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140, 691-707 (1992).
115. McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38, 1285-1291 (1988).
116. Muhleisen, H., Gehrmann, J. & Meyermann, R. Reactive microglia in Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 21, 505-517 (1995).
117. Xia, M. Q. & Hyman, B. T. Chemokines/chemokine receptors in the central nervous system and Alzheimer’s disease. J. Neurovirol. 5, 32-41 (1999).
118. Peyrin, J. M. et al. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport 10, 723-729 (1999).
119. Yates, S. L. et al. Amyloid- β and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J. Neurochem. 74, 1017-1025 (2000).
120. McGeer, P. L., Schulzer, M. & McGeer, E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 47, 425-432 (1996).
121. Wyss-Coray, T. Y. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc. Natl Acad. Sci. USA99, 10837-10842 (2002).
122. Schenk, D. et al. Immunization with amyloid-P attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
123. Morgan, D. et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408, 982-985 (2000).
124. Janus, C. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408, 979-982 (2000).
125. Schenk, D. Amyloid-β immunotherapy for Alzheimer’s disease: the end of the beginning. Nature Rev. Neurosci. 3, 824-828 (2002).
126. Tatzelt, J., Prusiner, S. B. & Welch, W. J. Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J. 15, 6363-6373 (1996).
127. Salomon, A. R., Marcinowski, K. J., Friedland, R. & Zagorski, M. G. Nicotine inhibits amyloid formation by the β -peptide. Biochemistry 35, 13568-13578 (1996).
128. Miroy, G. J. et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl Acad. Sci. USA 93, 15051-15056 (1996).
129. Villegas, V et al. Protein engineering as a strategy to avoid formation of amyloid fibrils. Protein Sci. 9, 1700-1708 (2000).
130. Coelho, T. et al. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromusc. Disord. 6, S20 (1996).
131. Alves, I. L., Hays, M. T. & Saraiva, M. J. Comparative stability and clearance of Met30 and Met119 transthyretin. Eur. J. Biochem. 249, 662-668 (1996).
132. Hammarstrom, P., Schneider, F. & Kelly, J. W. Trans- suppression of misfolding in an amyloid disease. Science 293, 2459-2462 (2001).
133. Perrier, V. et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl Acad. Sci. USA 99, 13079-13084 (2002).
134. Soto, C. et al. β -Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer’s therapy. Nature Med. 4, 822-826 (1998).
135. Permanne, B. et al. Reduction of amyloid load and cerebral damage in a transgenic animal model of Alzheimer’s disease by treatment with a P-sheet breaker peptide. FASEB J. 16, 860-862 (2002).
136. Soto, C. et al. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 355, 192-197 (2000).
137. Merlini, G. et al. Interaction of the anthracycline 4’-iodo-4’- deoxydoxorubicin with amyloid fibrils: inhibition of fibrillogenesis. Proc. Natl Acad. Sci. USA92, 2959-2964 (1995).
138. Forloni, G., Colombo, L., Girola, L., Tagliavini, F. & Salmona, M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 487, 404-407 (2001).
139. Aguzzi, A., Glatzel, M., Montrasio, F., Prinz, M. & Heppner, F. L. Interventional strategies against prion diseases. Nature Rev. Neurosci. 2, 745-749 (2001).
140. Sacchettini, J. C. & Kelly, J. W. Therapeutic strategies for human amyloid diseases. Nature Rev. Drug Discov. 1, 267-275 (2002).
141. LeVine, H. The challenge of inhibiting Aβ polymerization. Curr. Med. Chem. 9, 1121 -1133 (2002).
142. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101, 57-66 (2000).
143. Sigurdsson, E. M. et al. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161, 13-17 (2002).
144. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002).
145. Kisilevsky, R. et al. Arresting amyloidosis in vivo using small- molecule anionic sulphonates or sulphates: implications for Alzheimer’s disease. Nature Med. 1, 143-148 (1995).
146. Cherny, R. A. et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β -amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30, 665-676 (2001).
147. Fandrich, M., Fletcher, M. A. & Dobson, C. M. Amyloid fibrils from muscle myoglobin. Nature 410, 165-166 (2001).
148. Pertinhez, T. A. et al. Amyloid fibril formation by a helical cytochrome. FEBS Lett. 495, 184-186 (2001).